← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
ADCBiologicARCAGYGovitecanPhase 2

GCSF (GCSF)

Ovarian Cancer · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 20.4%임상시험 62상태 DISCONTINUED
ADCBiologicAmer Zureikatvedotin after avelumabPhase 2

Gemcitabine (Gemzar, Gemzar (Gemcitabine))

Pancreatic Cancer · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase2#인기#항체약물접합체+5
임상시험 62상태 DISCONTINUED
ADCBiologicAstraZenecaPhase 2

Goserelin (Goserelin)

Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 31%임상시험 62상태 RECRUITING
ADCBiologicMedical Enterprises Europe B.V.Phase 3

Mitomycin C (Mitomycin C)

Locally Advanced Cancer in the Anal Region · Urothelial Cancer

#UrothelialCancer#ADC#Phase3#인기#항체약물접합체+4
임상시험 62상태 RECRUITING
ADCBiologicIgenomixPhase 2

RNA analysis (RNA analysis)

Prostate Cancer · Adult Lymphocyte Depletion Hodgkin Lymph

#AdultLymphocyteDepletionHodgkinL#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 18%임상시험 62상태 ACTIVE
AntibodyBristol Myers SquibbPhase 2

Relatlimab (Relatlimab)

Various Advanced Cancer · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 71.4%임상시험 62상태 RECRUITING
ADCBiologicSuzhou Suncadia Biopharmaceutic…rezetecanPhase 3

SHR-A1811 (SHR-A1811)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
임상시험 62상태 RECRUITING
ADCBiologicQuantumLeap Healthcare Collabor…Phase 2

Standard Therapy (Standard Therapy)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 9%임상시험 62상태 RECRUITING
CGTBiologicShanghai Unicar-Therapy Bio-med…Phase 1

chimeric antigen receptor T cell (chimeric antigen receptor T cell)

Pancreatic Cancer; CAR · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 67%임상시험 62상태 ACTIVE
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Ado-trastuzumab emtansine, Ado-trastuzumab emtansine (T-DM1))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 77%임상시험 61상태 RECRUITING
CGTBiologicAlliance for Clinical Trials in…Phase 3

Allopurinol (Allopurinol)

B Acute Lymphoblastic Leukemia · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase3#인기#세포유전치료+5
임상시험 61상태 DISCONTINUED
AntibodyRochegovitecan in patients with …Phase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase3#인기#항체+4
효능 ORR 75%임상시험 61상태 ACTIVE
ADCBiologicOHSU Knight Cancer InstitutePhase 1

Bicalutamide (Bicalutamide)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 · FRα

#FR#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 19%임상시험 61상태 DISCONTINUED
ADCBiologicRelmada Therapeutics, Inc.deruxtecan improved objecti…Phase 2

Control treatment arm (Control treatment arm)

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 61상태 RECRUITING
ADCBiologicHoffmann-La RochePhase 2

Empagliflozin (Empagliflozin)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+2
임상시험 61상태 RECRUITING
ADCBiologicBioMérieuxderuxtecan plus fluoropyrim…Phase 2

Experimental treatment arm (Experimental treatment arm)

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 61상태 RECRUITING
ADCBiologicRegeneron PharmaceuticalsPhase 3

Prednisone/ prednisolone (Prednisone/ prednisolone)

Follicular Lymphoma (FL) · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 95%임상시험 61상태 RECRUITING
ADCBiologicAstellas Pharma Global Developm…Phase 3

TAS-102 (TAS-102)

Metastatic Colorectal Cancer · Gastric Cancer

#GastricCancer#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 20%임상시험 61상태 ACTIVE
CGTBiologicGlaxoSmithKlineSN-38 also augmented IL-10 …Phase 2

topotecan hydrochloride (topotecan hydrochloride)

Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 95.4%임상시험 61상태 DISCONTINUED
AntibodyRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE

6 / 75 페이지

← 이전다음 →